Equities research analysts expect Endologix, Inc. (NASDAQ:ELGX) to announce earnings per share of ($0.18) for the current quarter, according to Zacks. Five analysts have made estimates for Endologix’s earnings, with the highest EPS estimate coming in at ($0.13) and the lowest estimate coming in at ($0.23). Endologix reported earnings per share of ($0.11) during the same quarter last year, which would suggest a negative year over year growth rate of 63.6%. The firm is expected to announce its next quarterly earnings report on Tuesday, November 6th.
On average, analysts expect that Endologix will report full-year earnings of ($0.70) per share for the current year, with EPS estimates ranging from ($0.87) to ($0.57). For the next year, analysts expect that the firm will post earnings of ($0.59) per share, with EPS estimates ranging from ($0.73) to ($0.51). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Endologix.
Endologix (NASDAQ:ELGX) last issued its quarterly earnings data on Thursday, August 9th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.18). The firm had revenue of $44.70 million for the quarter, compared to the consensus estimate of $44.43 million. Endologix had a negative net margin of 40.92% and a negative return on equity of 61.15%. Endologix’s quarterly revenue was down 8.0% compared to the same quarter last year. During the same period last year, the firm posted ($0.10) EPS.
A number of analysts have commented on the stock. Stifel Nicolaus set a $3.00 price target on shares of Endologix and gave the stock a “hold” rating in a research report on Saturday. BMO Capital Markets reiterated a “hold” rating and issued a $4.00 target price on shares of Endologix in a report on Friday. Oppenheimer set a $4.00 target price on shares of Endologix and gave the stock a “hold” rating in a report on Friday. Piper Jaffray Companies downgraded shares of Endologix from an “overweight” rating to a “neutral” rating in a report on Friday. Finally, BidaskClub downgraded shares of Endologix from a “buy” rating to a “hold” rating in a report on Tuesday, August 7th. One research analyst has rated the stock with a sell rating and nine have assigned a hold rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $4.00.
Shares of ELGX stock traded down $1.75 during midday trading on Friday, reaching $2.99. 3,818,597 shares of the company were exchanged, compared to its average volume of 309,267. Endologix has a 12 month low of $2.66 and a 12 month high of $6.72. The company has a market capitalization of $398.21 million, a price-to-earnings ratio of -6.23 and a beta of 0.23. The company has a current ratio of 2.13, a quick ratio of 1.37 and a debt-to-equity ratio of 3.58.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MetLife Investment Advisors LLC purchased a new position in shares of Endologix in the fourth quarter worth approximately $236,000. Engineers Gate Manager LP purchased a new position in shares of Endologix in the second quarter worth approximately $442,000. Deutsche Bank AG increased its position in shares of Endologix by 111.7% in the fourth quarter. Deutsche Bank AG now owns 190,868 shares of the medical instruments supplier’s stock worth $1,019,000 after acquiring an additional 100,703 shares in the last quarter. C WorldWide Group Holding A S increased its position in shares of Endologix by 22.3% in the second quarter. C WorldWide Group Holding A S now owns 364,464 shares of the medical instruments supplier’s stock worth $2,063,000 after acquiring an additional 66,486 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. increased its position in shares of Endologix by 8.7% in the first quarter. Schwab Charles Investment Management Inc. now owns 380,648 shares of the medical instruments supplier’s stock worth $1,611,000 after acquiring an additional 30,585 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.
Featured Story: Short Selling
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.